GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Marketable Securities

Roquefort Therapeutics (LSE:ROQ) Marketable Securities : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Roquefort Therapeutics's Marketable Securities for the quarter that ended in Jun. 2024 was £0.00 Mil.


Roquefort Therapeutics Marketable Securities Historical Data

The historical data trend for Roquefort Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Marketable Securities Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Marketable Securities
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Marketable Securities Get a 7-Day Free Trial - - - - -

Roquefort Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Roquefort Therapeutics  (LSE:ROQ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Roquefort Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines